A Non St Elevation Acute Coronary Syndrome

Finally, one article was found by conducting a search of the identified article’s reference section. This article was searched by title on the Cochrane database and was found useful to the clinical

You are the nurse working in an anticoagulation clinic. K.N. is a patient who has a longstanding irregularly irregular heartbeat (atrial fi brillation, or A-fi b) for which he takes the oral anticoagulant warfarin (Coumadin). Recently, K.N. had his mitral heart valve replaced with a mechanical valve. You know that there are different PT/INR (prothrombin time/International Normalized Ratio) goal recommendations based on the indication for anticoagulation. (NOTE: PT has now been replaced by or is reported, in most cases, with INR [International Normalized Ratio], an international value that allows for laboratory standardization. PTT is more properly written

The evidence based practice process gives more evidence of young patients with few risk factors and no structural heart defect, the benefits of anticoagulation may be outweighed by the risks of haemorrhage (bleeding). High quality guidelines and the systematic searches used for the topic in this portfolio were beneficial. Use of a rigorous and transparent process in this portfolio for identifying, appraising and adopting/ adapting guidelines are crucial to help for the decision making. A major factor that stops the usage of the new drug is unfortunately, there are no specific antidotes to reverse the coagulant effects of the direct thrombin or factor Xa

Other outcomes were myocardial infarction, ischemic stroke, systemic thrombosis, venous thrombosis in other areas of the body besides the legs, and even death. The patients underwent assessment either in the clinic or by telephone at days 30, 90, 180, 270, and 360. This study was consistent with other studies in the fact that the use of rivaroxaban reduced the risk of recurrent venous thromboembolism by about 70%. Rivaroxaban was found to be more effective than aspirin for the prevention of recurrent venous thromboembolism and was associated with a smaller risk of bleeding. The primary outcome occurred in 17 out of the 1,107 individuals who received 20 mg of rivaroxaban and in 13 out of the 1,127 individuals who received 10 mg of rivaroxaban. This was compared to 50 out of the 1,131 individuals who received aspirin once a day. Rates of bleeding were 0.5% in individuals who received 20 mg of rivaroxaban, 0.4% in individuals who received 10 mg of rivaroxaban, and 0.3% in individuals who received aspirin. For patients with venous thromboembolism who continued anticoagulation the risk of a repetitive event was lower with rivaroxaban at both 20 mg and 10 mg of treatment doses rather than with

An extensive literature search was conducted regarding the topic of this paper. Databases utilized were: CINAHL, MEDLINE, PubMed, EbscoHost, and Google. Inclusion criteria included English language only research articles and publication dates ranging from 2009 to 2014

Current Treatment and Consideration of Evidence Base: Upon admission, patient was most-likely suspected of having ACS (acute coronary syndrome) because of CHD (coronary heart disease) (NICE, 2014c). Troponin T High Sensitivity Test was carried out to distinguish whether chest pains were because of NSTEMI or unstable angina (NICE, 2014b). This led to diagnosis of unstable angina. His current treatment with regards to drug interactions is okay, except that enoxaparin has a clinically significant interaction with aspirin (2015, p. 1199). This can be discounted for due to his condition.

Acute anterior NSTEMI, treated with PCI (Percutaneous Coronary Intervention with a Drug Eluting Stent) to LAD

In a hospital setting, anticoagulants and antiplatelets are widely prescribed by physicians because of their greater benefits in changing the physiological homeostasis of the cardiovascular system. Anticoagulants and antiplatelets play a fundamental role in the treatment of cardiovascular diseases as they are very effective at counteracting the different symptoms cardiovascular diseases present.

Dual antiplatelet therapy (DAPT), especially combination therapy with aspirin and clopidogrel, is recommended for the treatment of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).[1-2] Compared with aspirin or clopidogrel monotherapy, patients taking DAPT are much older and combine with more comorbidities. So they are more at the risk of encountering with stent thrombosis, revascularization, cardiogenic death, and so on. Antiplatelet drugs have been proved to dramatically cut down the risk of cardiovascular (CV) events, but also bring some side effects. Because antiplatelet drugs could damage gastrointestinal (GI) mucous membrane, patients are high-risk populations of overall GI adverse events that include GI bleeding,

In the current medical practices, there are several treatment options. The pharmaceutical industry produces so many drugs that perform similar functions (Chaitow&Schoenen, 2013). However, the pharmacokinetics of the drugs are quite different. Moreover, all the drugs in the market have different side effects and toxicity profiles. The same drug tends to behave differently in different people. Therefore, doctors are faced with hardships when choosing the best treatment option to adopt in particular patients. It is for this reason that evidence-based practice(EBP) was introduced.

New onset ST elevation is indicative of a myocardial infarction and is a condition that often requires either fibrinolytic therapy or angioplasty (O’Gara et al., 2013). The principal methods for determining acute coronary syndrome include the EKG and the cardiac enzyme troponin (O’Gara et al., 2013). The rapid ordering of these tests is especially useful during busy periods when there are delays in rooming a patient and receiving an evaluation by a physician.

Majority of the resources used in this paper were obtained through the University of Texas Rio Grande Valley Library website (http://www.utrgv.edu/library/find/databases/index.htm) and the University of Texas Rio Grande Valley School of Medicine Library website (http://www.utrgv.edu/medlibrary/index.htm). Both library searches returned over 1800 articles. After evaluating more than 200 articles, 50 of the articles’ abstracts were examined, then 17 articles were carefully chosen by the relevance of the subject matter to this analysis.

Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks and stroke.

Empagliflozin was compared with placebo and analyzed for effects on morbidity and mortality in patients with T2D at high risk for CV events who were receiving standard of care.

This review will aim to integrate our current understanding of the pharmacology of bivalirudin along with the clinical trials of bivalirudin reported to date.